Cargando…
Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality
SIMPLE SUMMARY: In this review, we discuss the potential use of extracellular vesicles (EVs) to deliver dietary supplements to the brain to reduce brain complications associated with HIV, COVID-19, and other brain disorders. Brain-related complications affect people with HIV and COVID-19 alike. More...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869385/ https://www.ncbi.nlm.nih.gov/pubmed/35205044 http://dx.doi.org/10.3390/biology11020177 |
_version_ | 1784656485183127552 |
---|---|
author | Kodidela, Sunitha Godse, Sandip Kumar, Asit Nguyen, Xuyen H. Cernasev, Alina Zhou, Lina Singh, Ajay Kumar Bhat, Hari K. Kumar, Santosh |
author_facet | Kodidela, Sunitha Godse, Sandip Kumar, Asit Nguyen, Xuyen H. Cernasev, Alina Zhou, Lina Singh, Ajay Kumar Bhat, Hari K. Kumar, Santosh |
author_sort | Kodidela, Sunitha |
collection | PubMed |
description | SIMPLE SUMMARY: In this review, we discuss the potential use of extracellular vesicles (EVs) to deliver dietary supplements to the brain to reduce brain complications associated with HIV, COVID-19, and other brain disorders. Brain-related complications affect people with HIV and COVID-19 alike. Moreover, since HIV patients are at a higher risk of contracting COVID-19, their neurological problems can be exacerbated by COVID-19. The use of dietary supplements together with available treatment options has been shown to reduce the severity of infections. However, these treatments are not chemically compatible with the body’s blood–brain barrier defense mechanism. Therefore, a viable delivery method is needed to deliver drugs and nutraceuticals to the brain in HIV and COVID-19 comorbid patients. ABSTRACT: People living with HIV/AIDS (PLWHA) are at an increased risk of severe and critical COVID-19 infection. There is a steady increase in neurological complications associated with COVID-19 infection, exacerbating HIV-associated neurocognitive disorders (HAND) in PLWHA. Nutraceuticals, such as phytochemicals from medicinal plants and dietary supplements, have been used as adjunct therapies for many disease conditions, including viral infections. Appropriate use of these adjunct therapies with antiviral proprieties may be beneficial in treating and/or prophylaxis of neurological complications associated with these co-infections. However, most of these nutraceuticals have poor bioavailability and cannot cross the blood–brain barrier (BBB). To overcome this challenge, extracellular vesicles (EVs), biological nanovesicles, can be used. Due to their intrinsic features of biocompatibility, stability, and their ability to cross BBB, as well as inherent homing capabilities, EVs hold immense promise for therapeutic drug delivery to the brain. Therefore, in this review, we summarize the potential role of different nutraceuticals in reducing HIV- and COVID-19-associated neurological complications and the use of EVs as nutraceutical/drug delivery vehicles to treat HIV, COVID-19, and other brain disorders. |
format | Online Article Text |
id | pubmed-8869385 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88693852022-02-25 Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality Kodidela, Sunitha Godse, Sandip Kumar, Asit Nguyen, Xuyen H. Cernasev, Alina Zhou, Lina Singh, Ajay Kumar Bhat, Hari K. Kumar, Santosh Biology (Basel) Review SIMPLE SUMMARY: In this review, we discuss the potential use of extracellular vesicles (EVs) to deliver dietary supplements to the brain to reduce brain complications associated with HIV, COVID-19, and other brain disorders. Brain-related complications affect people with HIV and COVID-19 alike. Moreover, since HIV patients are at a higher risk of contracting COVID-19, their neurological problems can be exacerbated by COVID-19. The use of dietary supplements together with available treatment options has been shown to reduce the severity of infections. However, these treatments are not chemically compatible with the body’s blood–brain barrier defense mechanism. Therefore, a viable delivery method is needed to deliver drugs and nutraceuticals to the brain in HIV and COVID-19 comorbid patients. ABSTRACT: People living with HIV/AIDS (PLWHA) are at an increased risk of severe and critical COVID-19 infection. There is a steady increase in neurological complications associated with COVID-19 infection, exacerbating HIV-associated neurocognitive disorders (HAND) in PLWHA. Nutraceuticals, such as phytochemicals from medicinal plants and dietary supplements, have been used as adjunct therapies for many disease conditions, including viral infections. Appropriate use of these adjunct therapies with antiviral proprieties may be beneficial in treating and/or prophylaxis of neurological complications associated with these co-infections. However, most of these nutraceuticals have poor bioavailability and cannot cross the blood–brain barrier (BBB). To overcome this challenge, extracellular vesicles (EVs), biological nanovesicles, can be used. Due to their intrinsic features of biocompatibility, stability, and their ability to cross BBB, as well as inherent homing capabilities, EVs hold immense promise for therapeutic drug delivery to the brain. Therefore, in this review, we summarize the potential role of different nutraceuticals in reducing HIV- and COVID-19-associated neurological complications and the use of EVs as nutraceutical/drug delivery vehicles to treat HIV, COVID-19, and other brain disorders. MDPI 2022-01-23 /pmc/articles/PMC8869385/ /pubmed/35205044 http://dx.doi.org/10.3390/biology11020177 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kodidela, Sunitha Godse, Sandip Kumar, Asit Nguyen, Xuyen H. Cernasev, Alina Zhou, Lina Singh, Ajay Kumar Bhat, Hari K. Kumar, Santosh Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality |
title | Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality |
title_full | Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality |
title_fullStr | Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality |
title_full_unstemmed | Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality |
title_short | Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality |
title_sort | nutraceuticals in hiv and covid-19-related neurological complications: opportunity to use extracellular vesicles as drug delivery modality |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869385/ https://www.ncbi.nlm.nih.gov/pubmed/35205044 http://dx.doi.org/10.3390/biology11020177 |
work_keys_str_mv | AT kodidelasunitha nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality AT godsesandip nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality AT kumarasit nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality AT nguyenxuyenh nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality AT cernasevalina nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality AT zhoulina nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality AT singhajaykumar nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality AT bhatharik nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality AT kumarsantosh nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality |